Evaluation of breast and gynecologic cancers by positron emission tomography

Seminars in Roentgenology

Volumn 37, Issue 2, 2002, Pages 151-168

  Dehdashti, Farrokh ^a   Siegel, Barry A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; DIAGNOSTIC AGENT;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; GYNECOLOGIC CANCER; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TECHNIQUE; UTERINE CERVIX CANCER; BREAST TUMOR; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE GENITAL TRACT TUMOR; METHODOLOGY; PREDICTION AND FORECASTING; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035996003     PISSN: 0037198X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-198X(02)80034-7     Document Type: Article

References (111)

1. Cancer statistics, 2001
2. Pathology and biological markers of invasive breast cancer
3. Natural history of breast cancer
4. Role and evaluation of mammography and other imaging methods for breast cancer detection, diagnosis, and staging
5. Effect of patients being prone during FDG PET for the diagnosis of breast cancer
6. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer
7. Breast masses: Mammographic evaluation
8. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
9. PET in breast cancer
10. Over expression of Glut-1 glucose transporter in human breast cancer: An immunohistochemical study
11. Serum glucose: Effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma
12. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important?
13. The application of positron emission tomography with fluorodeoxyglucose to the evaluation of breast disease
14. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy2-fluoro-D-glucose PET
15. 18F]fluoro-2-deoxy-D-glucose
16. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
17. Positron emission tomography and breast masses: Comparison with clinical, mammographic, and pathological findings
18. Positron tomographic assessment of estrogen receptors in breast cancer. Comparison with FDG-PET and in vitro receptor assays
19. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
20. 18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
21. Breast imaging with fluorine-18-FDG-PET: Quantitative image analysis
22. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium methoxyisobutylisonitrile scintimammography in the detection of breast tumors
23. 11C]tyrosine PET
24. Diagnostic value of positron emission tomography for detecting breast cancer
25. Positron emission tomography in breast cancer: A clinicopathological correlation of results
26. Breast imaging with positron emission tomography with fluorine-18 fluorodeoxyglucose: Use and limitations
27. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis
28. The potential of F-18-FDG-PET in breast cancer: Detection of primary lesions, axillary lymph node metastases, or distant metastases
29. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures
30. FDG positron emission tomography for evaluation of breast cancer
31. Positron emission mammographic instrument: Initial results
32. Technique to obtain positron emission mammography images in registration with x-ray mammograms
33. F-18 FDG uptake in breast infection and inflammation
34. Mammographic features of early breast cancer
35. The predictive value of certain mammographic signs in screening for breast cancer
36. MR imaging of the breast for detection, diagnosis, and staging breast cancer
37. Detection of breast mass after augmentation mammoplasty using 18-fluorodeoxyglucose-PET
38. Detection of cancer in augmented breasts by positron emission tomography
39. Local management of invasive breast cancer
40. 18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation
41. 18F]-D-glucose
42. 18F-PET: Histologic and immunohistochemical tissue analysis
43. The potential of 2-deoxy-2-fluoro-D-glucose (FDG) for detection of tumor involvernent in lymph nodes
44. Initial evaluation of FDG-PET for staging of the axilla in newly diagnosed breast cancer patients
45. Assessment of axillary lymph node involvement in breast patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
46. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry
47. 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: The experience of the national cancer institute of milan
48. Axillary lymph node metastases: Screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET
49. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer
50. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
51. Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients
52. Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer
53. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucosepositron emission tomography: Clinical evaluation and alternative management
54. Biology of bone metastases
55. 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions
56. 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases
57. 18F: I. Kinetics
58. Evaluation of skeletal kinetics of fluorine 18-fluoride ion with PET
59. Whole body skeletal imaging with [F-18] fluoride ion with PET
60. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET
61. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography
62. Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer
63. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
64. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
65. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
66. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
67. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy
68. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation
69. 18fluorodeoxygulcose positron emission tomography in the staging of recurrent breast carcinoma
70. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
71. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer
72. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience
73. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients
74. Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer
75. Estrogen and progesterone
76. The predictive value of estrogen and progesterone receptor's concentrations on the clinical behavior of breast cancer in women: Clinical correlation on 547 patients
77. Prognostic significance of progesterone receptor levels in estrogen receptorpositive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
78. Designing steroid receptor-based radiotracers to image breast and prostate tumors
79. Breast cancer: PET imaging of estrogen receptors
80. 18F]fluoro-17β-estradiol uptake in metastatic breast carcinoma
81. Clinical correlation of FDG and FES-PET imaging with estrogen receptor and response to systemic therapy
82. Tamoxifen flare in advanced breast cancer
83. Tamoxifen in the treatment of breast cancer
84. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer
85. [F-18]fluorodeoxyglucose (FDG) and 16α(F-18]fluoroestradiol-17β (FES) uptake in estrogen-receptor (ER)-rich tissues following tamoxifen treatment: A preclinical study
86. PET assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy
87. Metabolic flare: An indicator oh hormone responsiveness in advanced breast cancer
88. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
89. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
90. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: A surgicopathologic study
91. Metastatic lymph-nodes in patients with cervical cancer: Detection with MR imaging and FDG-PET
92. Detection of pelvic lymph node metastases in gynecologic malignancy: A comparison of CT, MR imaging and positron emission tomography
93. A comparison of MRI and PET scanning in surgically staged loco-regional advanced cervical cancer: Potential impact on treatment
94. FDG-PET evaluation of carcinoma of the cervix
95. Evaluation of FDG-PET in patients with cervical cancer
96. Positron emission tomography for evaluation of metastases in patients with carcinoma of the cervix: A retrospective review
97. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix
98. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy
99. Radiology in the management of ovarian cancer
100. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography
101. 18F]FDG)
102. Emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: Correlation with secondlook laparotomy
103. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma
104. Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels
105. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer
106. Experience with positron emission tomography (PET) scans in patients with ovarian cancer
107. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma
108. Similar pelvic abnormalities on FDG-PET positron emission tomography of different origins
109. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: Preliminary findings on positron emission tomography
110. FDG-PET evaluation of recurrent endometrial carcinoma
111. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer